Mr. Miscoll founded Ravello Precision Partners in 2015, which operated as a hedge fund focused on life science companies. Mr. Miscoll founded Ravello Partners LLC in 2010, which manages discretionary portfolios for families and small institutions and is active in the biotechnology sector. From 1999 until 2009, Mr. Miscoll was a Managing Director at Newlight Management, where he was responsible for managing all aspects of two private equity funds and a hedge fund focused on technology, media and communications companies. He originated and directed the firm’s public market investment activities. Previously, from 1994 to 1995, he was a Managing Director of Northgate Ventures, a venture capital fund focused on early stage technology companies. Mr. Miscoll was a founding member of the management team that created K-III Communications, a leveraged build-up in the publishing and information services industries sponsored by Kohlberg Kravis Roberts & Co.
Mr. Miscoll received an M.B.A. from Georgetown University, a Graduate Certificate from Templeton College, Oxford University, and a B.A. from Santa Clara University.
Mr. Wahlestedt, is Leonard M. Miller Professor and Director of the Center for Therapeutic Innovation at the University of Miami where he also serves as Associate Dean for Therapeutic Innovation. A native of Sweden, Dr. Wahlestedt obtained his MD and PhD degrees from Lund University. Prior to joining the University of Miami, Dr. Wahlestedt was a founding Professor and a Director at The Scripps Research Institute’s Florida campus. Between 1997 and 2005 he ran the Genome Center (one of the largest in Europe at the time) at the Karolinska Institute (Stockholm, Sweden) where he was also an endowed Professor and Department Chair. He has also been a faculty member at Cornell University Medical College and at McGill University. At different stages in his career, he has directed large R&D organizations in the pharmaceutical industry for Astra-Zeneca and for Pharmacia/Pfizer. In addition, he has co-founded several biotechnology companies and serves on various boards.
Mr. Lindroth is Chief Executive Officer of Lingfield AB, a company which serves as the internal corporate finance and investment management organization for a group of investment vehicles whose beneficiary owner is the Peder Wallenberg Charitable Trust. Before forming Lingfield in 1998, Mr. Lindroth served in various executive positions, from 1990 to 1998, at Marieberg AB, a newspaper publishing operation in Scandinavia. As a result of the above, Mr. Lindroth has both operational management experience as well as public and private equity investment expertise. Mr. Lindroth is a graduate of the University of Stockholm. He serves on the Board of Directors of Lingfield AB, Affectiva Inc., Midsummer AB, El Quseir Hotel Co., and Ceres Health.
Copyright © 2023 Ravello Partners LLC - All Rights Reserved.